pyrazines has been researched along with osteoprotegerin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roodman, GD | 1 |
| Berenson, JR | 1 |
| Mundy, GR; Oyajobi, BO | 1 |
| Hess, U | 1 |
| Cavallo, F; Esseltine, D; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Baum, W; Distler, JH; Frey, B; Gückel, E; Meister, S; Neubert, K; Polzer, K; Schett, G; Voll, RE; Zwerina, J | 1 |
| Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X; Zhao, S | 1 |
| Feng, J; Li, Z; Ma, Y; Ren, H; Wang, Y; Zhao, J | 1 |
| Baldock, PA; Kostenuik, PJ; Little, DG; McDonald, MM; Mikulec, K; Morse, A; Peacock, L | 1 |
3 review(s) available for pyrazines and osteoprotegerin
| Article | Year |
|---|---|
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Osteoprotegerin; Parathyroid Hormone; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
1 trial(s) available for pyrazines and osteoprotegerin
| Article | Year |
|---|---|
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
7 other study(ies) available for pyrazines and osteoprotegerin
| Article | Year |
|---|---|
Role of the bone marrow microenvironment in multiple myeloma.
Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Topics: Animals; Arthritis; Bone and Bones; Bone Resorption; Boronic Acids; Bortezomib; Cartilage, Articular; Chronic Disease; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RANK Ligand; Synovial Membrane; Tumor Necrosis Factor-alpha | 2011 |
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Arthroplasty, Replacement; Boronic Acids; Bortezomib; Female; Inflammation; Mice; Mice, Inbred BALB C; Osteolysis; Osteoprotegerin; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; RANK Ligand; Titanium; TNF Receptor-Associated Factor 6; Vascular Endothelial Growth Factors | 2012 |
Effects of brucine on bone metabolism in multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone and Bones; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Culture Media; Humans; Inhibitory Concentration 50; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteoprotegerin; Polymerase Chain Reaction; Pyrazines; RANK Ligand; RNA, Messenger; RNA, Neoplasm; Stem Cells; Strychnine | 2012 |
Matrix metalloproteinase-driven endochondral fracture union proceeds independently of osteoclast activity.
Topics: Animals; Bone Density Conservation Agents; Clodronic Acid; Collagenases; Diphosphonates; Femoral Fractures; Fracture Healing; Humans; Hydroxamic Acids; Imidazoles; Male; Matrix Metalloproteinase Inhibitors; Osteoclasts; Osteoprotegerin; Pyrazines; Rats; Rats, Wistar; Recombinant Proteins; Sulfonamides; Time Factors; Zoledronic Acid | 2013 |